{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:38:52Z","timestamp":1769553532067,"version":"3.49.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["21JCYBJC00180 19YFZCSY00420 18ZXDBSY00040"],"award-info":[{"award-number":["21JCYBJC00180 19YFZCSY00420 18ZXDBSY00040"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The COVID-19 outbreak triggered a serious and potentially lethal pandemic, resulting in massive health and economic losses worldwide. The most common clinical manifestations of COVID-19 patients are pneumonia and acute respiratory distress syndrome, with a variety of complications. Multiple organ failure and damage, ultimately leading to patient death, are possible as a result of medication combinations, and this is exemplified by DILI. We hope to summarize DILI caused by the antiviral drugs favipiravir, remdesivir, lopinavir\/ritonavir, and hydroxychloroquine in COVID-19 patients in this review. The incidence of liver injury in the treatment of COVID-19 patients was searched on PubMed to investigate DILI cases. The cumulative prevalence of acute liver injury was 23.7% (16.1%\u201333.1%). We discuss the frequency of these events, potential mechanisms, and new insights into surveillance strategies. Furthermore, we also describe medication recommendations aimed at preserving DILI caused by treatment in COVID-19 patients.<\/jats:p>","DOI":"10.3389\/fphar.2022.1019487","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T06:27:05Z","timestamp":1669616825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management"],"prefix":"10.3389","volume":"13","author":[{"given":"Xichuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weipeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiping","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.cmi.2021.05.020","article-title":"An open-label randomized controlled trial of the effect of lopinavir\/ritonavir, lopinavir\/ritonavir plus IFN-\u03b2-1a and hydroxychloroquine in hospitalized patients with COVID-19","volume":"27","author":"Ader","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijpharm.2007.02.036","article-title":"Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor","volume":"339","author":"Agarwal","year":"2007","journal-title":"Int. J. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/2050640620924157","article-title":"Liver injury in COVID-19: The current evidence","volume":"8","author":"Alqahtani","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-021-97160-3","article-title":"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics","volume":"11","author":"Ambrus","year":"2021","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B10","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.phrs.2020.104899","article-title":"Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status","volume":"158","author":"Antinori","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/hep.31326","article-title":"Liver biochemistries in hospitalized patients with COVID-19","volume":"73","author":"Bloom","year":"2021","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-642-14541-4_2","article-title":"In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy","author":"Burckhardt","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","article-title":"COVID-19: Abnormal liver function tests","volume":"73","author":"Cai","year":"2020","journal-title":"J. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17512433.2021.1856655","article-title":"Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications","volume":"14","author":"Charan","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"683296","DOI":"10.3389\/fphar.2021.683296","article-title":"Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: A prospective, multicenter, open-label, randomized controlled clinical trial","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3785\/j.issn.1008-9292.2020.03.03","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"B22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1124\/dmd.30.12.1344","article-title":"Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5","volume":"30","author":"Cook","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1517\/17425250903136748","article-title":"Long-term virus-induced alterations of CYP3A-mediated drug metabolism: A look at the virology, immunology and molecular biology of a multi-faceted problem","volume":"5","author":"Croyle","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13318-020-00668-8","article-title":"Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients","volume":"46","author":"Deb","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1124\/dmd.121.000430","article-title":"Comparative hepatic and intestinal efflux transport of statins","volume":"49","author":"Deng","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"B29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/00498254.2019.1655680","article-title":"Effects of dexamethasone to reverse decreased hepatic midazolam metabolism in rats with acute renal failure","volume":"50","author":"Doi","year":"2020","journal-title":"Xenobiotica."},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0006-2952(99)00026-x","article-title":"HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833","volume":"57","author":"Drewe","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2215\/CJN.09630818","article-title":"Clinical Pharmacology in diuretic use","volume":"14","author":"Ellison","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1590\/1516-3180.2021.0489.R1.13082021","article-title":"Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: A retrospective study","volume":"140","author":"Erg\u00fcr","year":"2022","journal-title":"Sao Paulo Med. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.4269\/ajtmh.20-0276","article-title":"Case report: Hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19","volume":"102","author":"Falc\u00e3o","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.cgh.2020.04.002","article-title":"Clinical features of COVID-19-related liver functional abnormality","volume":"18","author":"Fan","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/ijms23010082","article-title":"Molecular networking for drug toxicities studies: The case of hydroxychloroquine in COVID-19 patients","volume":"23","author":"Ferron","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.5858\/arpa.2014-0214-RA","article-title":"Drug-induced liver injury","volume":"139","author":"Fisher","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: An update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in patients with severe covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"33975","DOI":"10.1007\/s11356-020-09587-2","article-title":"Quantitative assessment of non-point source pollution load of PN\/PP based on RUSLE model: A case study in beiluo river basin in China","volume":"27","author":"Hao","year":"2020","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/FPC.0b013e328335b02d","article-title":"HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms","volume":"20","author":"Hartkoorn","year":"2010","journal-title":"Pharmacogenet. Genomics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1080\/07391102.2020.1767691","article-title":"Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): A simplified summary","volume":"39","author":"Hendaus","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B49","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/phar.2403","article-title":"Delayed initiation of remdesivir in a COVID-19-positive patient","volume":"40","author":"Hillaker","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"B51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1124\/dmd.117.079467","article-title":"MRP2 inhibition by HIV protease inhibitors in rat and human hepatocytes: A quantitative confocal microscopy study","volume":"46","author":"Holmstock","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"B52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2165\/00003088-199324030-00005","article-title":"Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure","volume":"24","author":"Hoyer","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/acer.12608","article-title":"Effects of combined alcohol and anti-HIV drugs on cellular stress responses in primary hepatocytes and hepatic stellate and kupffer cells","volume":"39","author":"Hu","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1097\/00002030-200211220-00009","article-title":"Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs","volume":"16","author":"Huisman","year":"2002","journal-title":"Aids"},{"key":"B56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4329\/wjr.v12.i7.137","article-title":"Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report","volume":"12","author":"Jafari","year":"2020","journal-title":"World J. Radiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: Review of Pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40266-021-00908-9","article-title":"Safety of remdesivir for patients 80 Years of age or older with coronavirus disease 2019 (COVID-19)","volume":"38","author":"Kanai","year":"2021","journal-title":"Drugs Aging"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1023\/a:1007568811691","article-title":"Inhibitory potencies of 1, 4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4","volume":"17","author":"Katoh","year":"2000","journal-title":"Pharm. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12098-022-04237-6","article-title":"Remdesivir-induced liver injury in a COVID-positive newborn","volume":"89","author":"Kaur","year":"2022","journal-title":"Indian J. Pediatr."},{"key":"B61","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/BF02976712","article-title":"Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes","volume":"26","author":"Kim","year":"2003","journal-title":"Arch. Pharm. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12072-020-10071-9","article-title":"Coronavirus disease (COVID-19) and the liver: A comprehensive systematic review and meta-analysis","volume":"14","author":"Kumar","year":"2020","journal-title":"Hepatol. Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.14218\/JCTH.2021.00011","article-title":"Favipiravir-induced liver injury in patients with coronavirus disease 2019","volume":"9","author":"Kumar","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B64","article-title":"Liver function tests","volume-title":"StatPearls. (Treasure island (FL)","author":"Lala","year":"2022"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: First approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"B66","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/01926230590522356","article-title":"Recognizing drug-induced liver injury: Current problems, possible solutions","volume":"33","author":"Lee","year":"2005","journal-title":"Toxicol. Pathol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/cid\/ciaa883","article-title":"Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of remdesivir with P-glycoprotein inhibitors","volume":"72","author":"Leegwater","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijpharm.2014.02.003","article-title":"In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1","volume":"465","author":"Li","year":"2014","journal-title":"Int. J. Pharm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.2147\/DDDT.S259058","article-title":"Antiviral agent therapy optimization in special populations of COVID-19 patients","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des. devel. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/00126334-200408150-00006","article-title":"Coadministration of lopinavir\/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction","volume":"36","author":"Lim","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell. Discov."},{"key":"B73","doi-asserted-by":"publisher","first-page":"105631","DOI":"10.1016\/j.ejps.2020.105631","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: An exploratory randomized, controlled trial","volume":"157","author":"Lou","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"0016220","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir against COVID-19 and other viral diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S2468-1253(20)30126-6","article-title":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis","volume":"5","author":"Mao","year":"2020","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/biology11010013","article-title":"Evaluation of hepatic biochemical parameters during antiviral treatment in COVID-19 patients","volume":"11","author":"Marc","year":"2021","journal-title":"Biol. (Basel)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40268-020-00333-0","article-title":"Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment","volume":"21","author":"Marra","year":"2021","journal-title":"Drugs R. D."},{"key":"B78","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/hep4.1843","article-title":"Covid-19 and liver injury: Role of inflammatory endotheliopathy, platelet dysfunction, and thrombosis","volume":"6","author":"McConnell","year":"2021","journal-title":"Hepatol. Commun."},{"key":"B79","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.ajogmf.2020.100164","article-title":"Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center","volume":"2","author":"Mccoy","year":"2020","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"B80","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0009-9236(99)70114-1","article-title":"Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174","volume":"65","author":"Mccrea","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/pgs.10.171","article-title":"Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse","volume":"12","author":"Meyer","year":"2011","journal-title":"Pharmacogenomics"},{"key":"B82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejps.2010.05.016","article-title":"Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays","volume":"41","author":"Muni\u0107","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0009-9236(96)90167-8","article-title":"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid","volume":"60","author":"Neuvonen","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/pharmaceutics13030369","article-title":"Interaction of remdesivir with clinically relevant hepatic drug uptake transporters","volume":"13","author":"Nies","year":"2021","journal-title":"Pharmaceutics"},{"key":"B85","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-020-00966-9","article-title":"Lopinavir-ritonavir in the treatment of COVID-19: A dynamic systematic benefit-risk assessment","volume":"43","author":"Osborne","year":"2020","journal-title":"Drug Saf."},{"key":"B86","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/toxsci\/kft197","article-title":"Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP\/ABCB11)","volume":"136","author":"Pedersen","year":"2013","journal-title":"Toxicol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/0091270005284853","article-title":"Pharmacokinetics of lopinavir\/ritonavir in HIV\/hepatitis C virus-coinfected subjects with hepatic impairment","volume":"46","author":"Peng","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jps.1133","article-title":"Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line","volume":"90","author":"Perloff","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/1060028020925558","article-title":"Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19","volume":"54","author":"Piszczatoski","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"n1038","DOI":"10.1136\/bmj.n1038","article-title":"Use of repurposed and adjuvant drugs in hospital patients with Covid-19: Multinational network cohort study","volume":"373","author":"Prats-Uribe","year":"2021","journal-title":"BMJ Clin. Res. Ed.)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/00002030-199909100-00004","article-title":"Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors","volume":"13","author":"Profit","year":"1999","journal-title":"Aids"},{"key":"B92","doi-asserted-by":"publisher","first-page":"119490","DOI":"10.1016\/j.ijpharm.2020.119490","article-title":"Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations","volume":"3","author":"Sahakijpijarn","year":"2021","journal-title":"Int. J. Pharm."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e0236778","DOI":"10.1371\/journal.pone.0236778","article-title":"Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease","volume":"15","author":"Satlin","year":"2020","journal-title":"PLoS One"},{"key":"B94","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41591-020-0849-9","article-title":"Lopinavir-ritonavir in severe COVID-19","volume":"26","author":"Stower","year":"2020","journal-title":"Nat. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jmv.24988","article-title":"HBV, HCV, and HBV\/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome","volume":"90","author":"Su","year":"2018","journal-title":"J. Med. Virol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"9437043","DOI":"10.1155\/2019\/9437043","article-title":"Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies","volume":"2019","author":"Sucher","year":"2019","journal-title":"J. Immunol. Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1177\/0961203318768884","article-title":"The devil's in the dosing: Severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda","volume":"27","author":"Sunkara","year":"2018","journal-title":"Lupus"},{"key":"B98","first-page":"294","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites","volume":"282","author":"Sutton","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.diabres.2005.09.019","article-title":"Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes","volume":"72","author":"Suzuki","year":"2006","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22037\/ijpr.2021.115510.15401","article-title":"Favipiravir effects on the control of clinical symptoms of hospitalized COVID-19 cases: An experience with Iranian formulated dosage form","volume":"20","author":"Tabarsi","year":"2021","journal-title":"Iran. J. Pharm. Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41525-020-00143-y","article-title":"Pharmacogenomics of COVID-19 therapies","volume":"5","author":"Takahashi","year":"2020","journal-title":"NPJ Genom. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s11096-021-01311-5","article-title":"Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: A disproportionality analysis of U.S. Food and drug administration adverse event reporting system (FAERS) data","volume":"43","author":"Tang","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/009127009203201207","article-title":"The influence of diltiazem versus cimetidine on propranolol metabolism","volume":"32","author":"Tateishi","year":"1992","journal-title":"J. Clin. Pharma."},{"key":"B104","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1111\/bcp.14831","article-title":"Liver and kidney function in patients with Covid-19 treated with remdesivir","volume":"87","author":"Van Laar","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): From mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz","year":"2021","journal-title":"Antioxidants (Basel, Switz."},{"key":"B107","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40779-020-00256-6","article-title":"Pattern of liver injury in adult patients with COVID-19: A retrospective analysis of 105 patients","volume":"7","author":"Wang","year":"","journal-title":"Mil. Med. Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1211\/002235702739","article-title":"Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir","volume":"55","author":"Weemhoff","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"E919","DOI":"10.3390\/pharmaceutics12100919","article-title":"Interaction of hydroxychloroquine with pharmacokinetically important drug transporters","volume":"12","author":"Weiss","year":"2020","journal-title":"Pharmaceutics"},{"key":"B111","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1097\/01.aids.0000183626.74299.77","article-title":"MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells","volume":"19","author":"Woodahl","year":"2005","journal-title":"Aids"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/liv.14449","article-title":"Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study","volume":"40","author":"Xie","year":"2020","journal-title":"Liver Int."},{"key":"B114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B115","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/cts.12815","article-title":"What do we know about remdesivir drug interactions?","volume":"13","author":"Yang","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/bdd.701","article-title":"Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes","volume":"31","author":"Ye","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"key":"B117","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cld.2013.07.002","article-title":"Mechanisms of drug induced liver injury","volume":"17","author":"Yuan","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"106445","DOI":"10.1016\/j.dib.2020.106445","article-title":"Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients","volume":"33","author":"Zanon","year":"2020","journal-title":"Data Brief."},{"key":"B119","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","article-title":"Liver injury in COVID-19: Management and challenges","volume":"5","author":"Zhang","year":"","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B120","first-page":"360","article-title":"Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor","volume":"26","author":"Zhang","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/liv.14455","article-title":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in wuhan city, China","volume":"40","author":"Zhang","year":"","journal-title":"Liver Int."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B123","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1002\/jmv.25884","article-title":"Clinical characteristics of 3062 COVID-19 patients: A meta-analysis","volume":"92","author":"Zhu","year":"","journal-title":"J. Med. Virol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"","journal-title":"J. Infect."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1019487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T06:27:15Z","timestamp":1669616835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1019487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":125,"alternative-id":["10.3389\/fphar.2022.1019487"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1019487","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"article-number":"1019487"}}